About SOFIE
SOFIE is a company based in Culver City (United States) founded in 2008. SOFIE has raised $43.1 million across 13 funding rounds from investors including DOE, National Cancer Institute and Jubilant Pharma. The company has 546 employees as of December 31, 2023. SOFIE has completed 1 acquisition, including Zevacor. SOFIE offers products and services including Tracers, Contract Manufacturing, and Education Programs. SOFIE operates in a competitive market with competitors including Advanced Accelerator Applications, AdvanCell, Ariceum Therapeutics, Mariana Oncology and ARTBIO, among others.
- Headquarter Culver City, United States
- Employees 546 as on 31 Dec, 2023
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sofie Biosciences
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SOFIE
SOFIE offers a comprehensive portfolio of products and services, including Tracers, Contract Manufacturing, and Education Programs.
Products for molecular imaging and diagnostics in patients.
Manufacturing services for clinical radiopharmaceutical needs.
Programs to enhance PET technology and patient care.
People of SOFIE
Unlock access to complete
Unlock access to complete
Funding Insights of SOFIE
SOFIE has successfully raised a total of $43.1M across 13 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SOFIE
SOFIE has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include DOE, National Cancer Institute and Jubilant Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage agnostic VC firm investing primarily in the US
|
Locked | Locked | Locked | |
|
Private equity investments are targeted at North American companies.
|
Locked | Locked | Locked | |
|
Scientific and technical information is managed and disseminated by OSTI.GOV.
|
Locked | Locked | Locked |
Investor details for SOFIE
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SOFIE
SOFIE has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Zevacor.
Investment portfolio details for SOFIE
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Radiolabeling & radiopharmaceutical manufacturing services for nuclear medicine and molecular imaging
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for SOFIE
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - SOFIE
Detailed financials for SOFIE
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sofie Comparisons
Peer comparison for SOFIE
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SOFIE
SOFIE operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advanced Accelerator Applications, AdvanCell, Ariceum Therapeutics, Mariana Oncology and ARTBIO, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Radiopharmaceutical company developing targeted alpha therapies for cancer treatment
|
|
| Locked | Locked | Locked |
Developer of drugs for systemic targeted radiation therapy to treat cancer
|
|
| Locked | Locked | Locked |
Targeted radiopharmaceuticals for solid tumors are developed and pioneered.
|
|
| Locked | Locked | Locked |
Alpha radioligand therapies for cancer are developed using lead-212.
|
Detailed competitors of SOFIE
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sofie
Complete news archive for SOFIE
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SOFIE
SOFIE was founded in 2008 and raised its 1st funding round 2 years after it was founded.
SOFIE is headquartered in Culver City, United States. It is registered at Culver City, California, United States.
Patrick Phelps is the current CEO of SOFIE.
SOFIE is a funded company, having raised a total of $43.1M across 13 funding rounds to date.
As of Dec 31, 2023, the latest employee count at SOFIE is 546.
Sofie Biosciences is developing molecular imaging systems and radio-pharmaceuticals. The companys molecular imaging device uses positron emission tomography (PET). Its other products include radiochemistry synthesizers, small animal PET imaging cameras, PET probes. The companys products are used for diagnosis, staging, and treatment evaluation in oncology, neurology, cardiology, and immunology.
SOFIE's top competitors include Advanced Accelerator Applications, AdvanCell and Mariana Oncology.
SOFIE offers Tracers, Contract Manufacturing, and Education Programs.
SOFIE has made 1 acquisition, including Zevacor.
SOFIE has 7 investors. Key investors include DOE, National Cancer Institute, Jubilant Pharma, OSTI.GOV, and Cycad Group.